drugset
drugset / Trial / NCT06618313

One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL

NCT06618313 ↗

Recruiting 8 enrolled Beijing GoBroad Hospital Ruijin Hospital · collab
NaSequentialOpen-labelTreatment

Summary

Evaluate the Safety and Efficacy of JCXH-213 in Patients with Relapsed/Refractory B-cell non-Hodgkin Lymphoma

Timeline

Start
2025-03-27
Primary completion
2026-08
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject JCXH-213 Messenger RNA (mRNA) — Other

Indications

B-cell non-Hodgkin lymphoma